Sugi Predict

Sugi Predict / Compounds / SCHEMBL456673

SCHEMBL456673

SCHEMBL456673

Cn1ncc2c(C(=O)O)cc(Br)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ AKR1C3 P42330 2/20 0.40
▸ AKR1C2 P52895 2/20 0.40
▸ AKR1C1 Q04828 2/20 0.40
▸ AKR1C4 P17516 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ MCL1 Q07820 1/20 0.36
▸ MYC P01106 1/20 0.36
▸ NR4A1 P22736 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KMO O15229 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4C Q9H3R0 1/20 0.34
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766050 1.00 IDO1 (0.41) IDO1TDO2KDM4EALDH1A1AKR1C3
SCHEMBL23115827 0.86 IDO1 (0.41) IDO1TDO2KDM4EALDH1A1HSD17B10
SCHEMBL19150141 0.84 IDO1 (0.44) IDO1TDO2KDM4EALDH1A1NPC1
SCHEMBL456891 0.83 CYP1A2 (0.42) IDO1TDO2HSD17B10KMT2A
SCHEMBL26581097 0.82 KDM4E (0.44) KDM4EALDH1A1HSD17B10MYCKMO
SCHEMBL2588357 0.81 KMO (0.43) KDM4EAKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL4719891 0.81 KDM4E (0.40) KDM4EALDH1A1HSD17B10SMN1; SMN2KMT2A
SCHEMBL31474839 0.80 KDM4E (0.53) KDM4EAKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL2587830 0.80 KMO (0.39) KDM4EALDH1A1AKR1C3AKR1C2AKR1C1
SCHEMBL2588942 0.80 KDM4E (0.53) KDM4EAKR1C3AKR1C2AKR1C1AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297190-B2 Modulators of STING (stimulator of interferon genes) PFIZER INC. (US) 2025-05-13 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
EP-4168411-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-04-26 — — EP disclosed
US-20230056253-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-23 — — US disclosed
EP-4034534-A1 POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) Pfizer Inc. (US) 2022-08-03 — — EP disclosed
CN-114728946-A Polyheterocyclic modulators of STING (stimulator of interferon genes) 辉瑞公司 2022-07-08 — — CN disclosed
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 — — EP disclosed
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 — — EP disclosed
EP-2613781-A1 INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-17 — — EP disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 — — US disclosed
US-20130165433-A1 Novel Use GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-06-27 — — US disclosed
WO-2012032065-A1 INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION GLAXO GROUP LIMITED (GB) 2012-03-15 — — WO disclosed
US-20120053166-A1 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
US-20120053166-A1 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
US-20120053166-A1 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases GLAXO GROUP LIMITED (GB) 2012-03-01 — — US disclosed
EP-2406255-A1 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES Glaxo Group Limited (GB) 2012-01-18 — — EP disclosed
WO-2010102958-A1 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES GLAXO GROUP LIMITED (GB) 2010-09-16 — — WO disclosed
WO-2010102958-A1 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES GLAXO GROUP LIMITED (GB) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297190-B2 Modulators of STING (stimulator of interferon genes) STING1, IRF3, CGAS IDO1 785/4885TDO2 4156/4885KDM4E 3785/4885
US-20230056253-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS IDO1 4420/4885TDO2 4087/4885KDM4E 3236/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS IDO1 4420/4885TDO2 4087/4885KDM4E 3236/4885
US-20130165433-A1 Novel Use HAVCR2, MAVS, ENTPD5 IDO1 113/4885TDO2 2952/4885KDM4E 3214/4885
US-20120053166-A1 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases CDK3, CDK13, AKT3 IDO1 1459/4885TDO2 3188/4885KDM4E 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.